Christopher Heery - Feb 7, 2023 Form 4 Insider Report for Arcellx, Inc. (ACLX)

Role
Chief Medical Officer
Signature
/s/ Michelle Gilson, as Attorney-in-Fact
Stock symbol
ACLX
Transactions as of
Feb 7, 2023
Transactions value $
-$214,333
Form type
4
Date filed
2/9/2023, 06:26 PM
Previous filing
Feb 7, 2023
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACLX Common Stock Options Exercise $0 +22.6K $0.00 22.6K Feb 7, 2023 Direct F1
transaction ACLX Common Stock Sale -$214K -6.97K -30.88% $30.77 15.6K Feb 9, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACLX Restricted Stock Unit Options Exercise $0 -22.6K -33.33% $0.00 45.1K Feb 7, 2023 Common Stock 22.6K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean February 7, 2022.